Plasma kallikrein inhibitors

A compound of the formula:

• wherein X is N or CH;
• R1 is selected from the group consisting of hydrogen, halo, hydroxy and C1-6 alkyl;
• R2 is selected from the group consisting of hydrogen, halo, hydroxy and C1-6 alkyl;
• R3 is selected from the group consisting of hydrogen, halo, hydroxy and C1-6 alkyl, wherein said alkyl group is optionally substituted with one to four substituents independently selected from the group consisting of halo, cyano and ORx;
• R4 is selected from the group consisting of hydrogen, halo, hydroxy and C1-6 alkyl;
• wherein said alkyl group is optionally substituted with one to four substituents independently selected from the group consisting of halo, cyano and ORx;
• R5 is NR9R10 or ORx;
• each R6 is independently selected from the group consisting of hydrogen, halo, hydroxy and C1-6 alkyl, wherein said alkyl group is optionally substituted with one to three halo;
• each R7 is selected from the group consisting of hydrogen, halo, hydroxy and C1-6 alkyl, wherein said alkyl group is optionally substituted with one to three halo;
• or R6 and R7 can be taken together with the carbon atom to which they are attached to form a 3-6 membered cycloalkyl group, which is optionally substituted with one or two halo;
• R8 is selected from the group consisting of hydrogen;
• halo;
• hydroxy;
• Rx;
• ORx;
• phenyl;
• indane;
• ORy;
• heteroaryl, which can be monocyclic or bicyclic;
• heterocyclyl;
• and C3-6 cycloalkyl, which can be monocyclic or bicyclic;
• wherein said phenyl and heteroaryl groups are optionally substituted with one to three substituents independently selected from the group consisting of oxo, halo, Rx, ORx, NR9R10, NR9(C═O)Rx, NR9(C═O)ORx, (C═O)ORx, (C═O)NR9, Ry and ORy;
• wherein said cycloalkyl and heterocyclyl groups are optionally substituted with one to three substituents independently selected from the group consisting of oxo, halo, Rx and ORx;
• R9 is hydrogen or C1-3 alkyl;
• R10 is hydrogen or C1-3 alkyl;
• Rx is hydrogen or C1-6 alkyl, which is optionally substituted with one to three substituents selected from the group consisting of halo and hydroxy,
• Ry is phenyl, heterocyclyl or C3-6 cycloalkyl, wherein said phenyl group is optionally substituted with one to three halo, said heterocyclyl group is optionally substituted with one or two oxo and said cycloalkyl group is optionally substituted with C1-6 alkyl;
• and n is an integer from zero to two;
• or a pharmaceutically salt thereof.